Methotrexate in psoriasis and psoriatic arthritis

Methotrexate in psoriasis and psoriatic arthritis

Methotrexate (MTX) is the most commonly prescribed first-line therapy in psoriatic arthritis (PsA) internationally and is also commonly used in the treatment of psoriasis. However, data supporting its use in PsA are limited and significant toxicities can occur. This article summarises a debate at th...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Coates, L, Merola, J, Grieb, SM, Mease, PJ, Duffin, KC
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	Journal of Rheumatology 2020

Eitemau Tebyg

Identification of psoriatic arthritis in patients with psoriasis
gan: Coates, LC, et al.
Cyhoeddwyd: (2023)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
gan: Coates, L, et al.
Cyhoeddwyd: (2016)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
gan: Coates, LC, et al.
Cyhoeddwyd: (2022)

Should methotrexate have any place in the treatment of psoriatic arthritis?
gan: Ye, W, et al.
Cyhoeddwyd: (2019)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
gan: Coates, L, et al.
Cyhoeddwyd: (2020)

Hot topice debate: preventing psoriatic arthritis in patients with psoriasis
gan: Vivekanantham, A, et al.
Cyhoeddwyd: (2024)

Is axial psoriatic arthritis the same as ankylosing spondylitis with psoriasis: a debate
gan: Coates, LC, et al.
Cyhoeddwyd: (2023)

New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation
gan: Coates, L, et al.
Cyhoeddwyd: (2016)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology consensus‐based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis
gan: Coates, L, et al.
Cyhoeddwyd: (2017)

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
gan: Mease, P, et al.
Cyhoeddwyd: (2018)

2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis
gan: Singh, JA, et al.
Cyhoeddwyd: (2018)

Measuring outcomes in psoriatic arthritis
gan: Ogdie, A, et al.
Cyhoeddwyd: (2020)

Patient education and screening for psoriatic arthritis is key in the care of patients with psoriasis, whichever method is chosen
gan: Coates, L
Cyhoeddwyd: (2017)

Psoriatic arthritis
gan: FitzGerald, O, et al.
Cyhoeddwyd: (2021)

Considerations for the definition of remission criteria in psoriatic arthritis
gan: Mease, P, et al.
Cyhoeddwyd: (2017)

Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis
gan: Coates, L, et al.
Cyhoeddwyd: (2018)

The role of epigenetics and immunological imbalance in the etiopathogenesis of psoriasis and psoriatic arthritis
gan: Frischknecht, L, et al.
Cyhoeddwyd: (2019)

2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis
gan: Singh, J, et al.
Cyhoeddwyd: (2018)

2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis
gan: Singh, J, et al.
Cyhoeddwyd: (2018)

Cell and tissue specific functional genomics of psoriasis and psoriatic arthritis
gan: Lledo Lara, A
Cyhoeddwyd: (2019)

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
gan: Nash, P, et al.
Cyhoeddwyd: (2020)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
gan: Ogdie, A, et al.
Cyhoeddwyd: (2023)

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
gan: Palfreeman, A, et al.
Cyhoeddwyd: (2013)

Screening/referral strategies for the early recognition of psoriatic arthritis (PsA) among patients with psoriasis: results of a GRAPPA survey
gan: Song, K, et al.
Cyhoeddwyd: (2023)

Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
gan: Poddubnyy, D, et al.
Cyhoeddwyd: (2021)

Classification and outcome measures for psoriatic arthritis
gan: Leung, Y, et al.
Cyhoeddwyd: (2018)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
gan: Gladman, DD, et al.
Cyhoeddwyd: (2018)

Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies
gan: Alinaghi, F, et al.
Cyhoeddwyd: (2018)

Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial
gan: Kavanaugh, A, et al.
Cyhoeddwyd: (2024)

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity
gan: Mease, PJ, et al.
Cyhoeddwyd: (2019)

Enhanced surveillance for the detection of psoriatic arthritis in a UK primary care psoriasis population: results from the TUDOR trial
gan: McHugh, N, et al.
Cyhoeddwyd: (2024)

Psoriatic arthritis: prospects for the future
gan: Hackett, S, et al.
Cyhoeddwyd: (2022)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
gan: Coates, L, et al.
Cyhoeddwyd: (2017)

The road to personalised medicine in psoriatic arthritis
gan: White, JPE, et al.
Cyhoeddwyd: (2021)

Clinical, genetic and omics-based biomarkers that might support the identification of the development of psoriatic arthritis in individuals with psoriasis – a narrative review of the literature
gan: Grohmann, T, et al.
Cyhoeddwyd: (2024)

Radiographic efficacy of adalimumab in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use and clinical response: subanalysis of adept
gan: Choy, E, et al.
Cyhoeddwyd: (2007)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
gan: Coates, LC, et al.
Cyhoeddwyd: (2022)

Adalimumab treatment with and without methotrexate in patients with moderate to severe psoriatic arthritis: Results from adept
gan: Kavanaugh, A, et al.
Cyhoeddwyd: (2005)

Identifying mediators of pain reduction in patients with psoriatic arthritis treated with tofacitinib: Role of inflammation associated with peripheral arthritis, enthesitis and skin disease
gan: Taylor, PC, et al.
Cyhoeddwyd: (2020)

Remission in psoriatic arthritis—where are we now?
gan: Coates, L, et al.
Cyhoeddwyd: (2017)